-
-
-
-
-
-
-
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
-
-
-
-
-
-
-
2seventy bio, Inc. (TSVT) Misses Q1 EPS by 26c
-
-
-
-
-
-
-
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
-
-
-
-
-
-
-
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
-
-
-
-
-
-
-
2seventy bio (TSVT) Announces Strategic Restructuring, CEO to Step Down
-
-
-
-
-
-
-
2seventy bio (TSVT) and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15M Preclinical Milestone
-
-
-
-
-
-
-
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

